Last updated: 2026-09-10 15:44:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
PolyPid Ltd. (PYPD) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $5,23, with a market capitalization of $108,26M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3,06 to $5,73. This page covers its latest market performance, valuation, price trends and company information.
$108,26M | |
$5,20 | |
$583,50 | |
$2,30 | |
$5,20 | |
18,82K | |
213,28K | |
-- | |
$5,73 | |
$3,06 | |
-- | |
-- |
PolyPid Ltd. (PYPD) is currently trading at $5,23 as of 2026-09-10 15:43:00, up 0,48% ($0,02) from the previous close of $5,20
During today's regular trading session, PYPD has traded between $2,30 and $583,50, with a trading volume of 18,82K shares. The current price is near the lower end of today's range.
Over the past seven days, PolyPid Ltd. (PYPD) moved from $5,14 to $5,23, representing a gain of 1,65% ($0,08).
The stock traded between $5,00 and $5,57 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 115,68 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 81,1%
PYPD is currently trading at $5,23, placing it 81,1% of the way from its 52-week low of $3,06 to its 52-week high of $5,73. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
| Employees | 75 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of PolyPid Ltd. (PYPD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.